Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) PT at $19.00

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $19.00.

Several research firms recently commented on ARTV. HC Wainwright boosted their price objective on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. Finally, Jefferies Financial Group upgraded Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th.

Artiva Biotherapeutics Trading Down 0.2%

Shares of Artiva Biotherapeutics stock opened at $5.46 on Monday. The business has a fifty day simple moving average of $4.51 and a two-hundred day simple moving average of $3.81. The firm has a market capitalization of $134.04 million, a P/E ratio of -2.12 and a beta of 2.16. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $7.36.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently bought and sold shares of the company. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the 3rd quarter valued at about $41,000. Bank of America Corp DE lifted its stake in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $48,000. Bridgeway Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $53,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $58,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.